SLDB stock forecast
Our latest prediction for Solid Biosciences, Inc.'s stock price was made on the March 28, 2019 when the stock price was at 9.59$.
In the short term (2weeks), SLDB's stock price should underperform the market by -1.22%. During that period the price should oscillate between -11.74% and +21.17%.
In the medium term (3months), SLDB's stock price should outperform the market by 1.41%. During that period the price should oscillate between -24.68% and +52.69%.Get email alerts
Create a solid portfolio with SLDB
About Solid Biosciences, Inc.
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.25$ per share.
The book value per share is 4.58$
Three months stock forecastMarch 28, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|